Cargando…

Unraveling Vulnerabilities in Endocrine Therapy-Resistant HER2+/ER+ Breast Cancer

BACKGROUND: Breast tumors overexpressing human epidermal growth factor receptor (HER2) confer intrinsic resistance to endocrine therapy (ET), and patients with HER2/ estrogen receptor-positive (HER2+/HR+) breast cancer (BCa) are less responsive to ET than HER2−/ER+. However, real-world evidence reve...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bahnassy, Shaymaa, Stires, Hillary, Jin, Lu, Tam, Stanley, Mobin, Dua, Balachandran, Manasi, Podar, Mircea, McCoy, Matthew D., Beckman, Robert A., Riggins, Rebecca B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cold Spring Harbor Laboratory 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10473676/ https://www.ncbi.nlm.nih.gov/pubmed/37662291 http://dx.doi.org/10.1101/2023.08.21.554116

Ejemplares similares

OR16-5 Riluzole suppresses growth and enhances response to endocrine therapy in ER+ breast cancer
por: Bahnassy, Shaymaa, et al.
Publicado: (2022)

Riluzole Suppresses Growth and Enhances Response to Endocrine Therapy in ER+ Breast Cancer
por: Olukoya, Ayodeji O, et al.
Publicado: (2023)

SAT-119 Targeting Glutamate Metabolism and Signaling in ER+, Endocrine Therapy-Resistant Breast Cancer
por: Olukoya, Ayodeji O, et al.
Publicado: (2020)

ROS is a master regulator of in vitro matriptase activation
por: Gaymon, Darius O., et al.
Publicado: (2023)

EGFR/HER2 inhibitor AEE788 increases ER-mediated transcription in HER2/ER-positive breast cancer cells but functions synergistically with endocrine therapy
por: Evans, A H, et al.
Publicado: (2010)

Candidate methylation sites associated with endocrine therapy resistance in ER+/HER2- breast cancer
por: Soleimani Dodaran, Maryam, et al.
Publicado: (2020)

Constitutively active androgen receptor supports the metastatic phenotype of endocrine-resistant hormone receptor-positive breast cancer
por: Bahnassy, Shaymaa, et al.
Publicado: (2020)

Comparison of metabolic changes after neoadjuvant endocrine and chemotherapy in ER-positive, HER2-negative breast cancer
por: Ryu, Ho Hyun, et al.
Publicado: (2021)

Functional Characterization of Circulating Tumor Cells (CTCs) from Metastatic ER+/HER2− Breast Cancer Reveals Dependence on HER2 and FOXM1 for Endocrine Therapy Resistance and Tumor Cell Survival: Implications for Treatment of ER+/HER2− Breast Cancer
por: Roßwag, Sven, et al.
Publicado: (2021)

Prognostic value of breast MRI characteristics before and during neoadjuvant endocrine therapy in patients with ER+/HER2- breast cancer
por: Ragusi, Max AA, et al.
Publicado: (2021)

Peroral Estradiol Is Sufficient to Induce Carcinogen-Induced Mammary Tumorigenesis in Ovariectomized Rats without Progesterone
por: Stires, Hillary, et al.
Publicado: (2016)

Endoplasmic Reticulum (ER) Stress and Endocrine Disorders
por: Ariyasu, Daisuke, et al.
Publicado: (2017)

Plasma thymidine kinase 1 activity and outcome of ER+ HER2− metastatic breast cancer patients treated with palbociclib and endocrine therapy
por: Cabel, Luc, et al.
Publicado: (2020)

Endocrine Activity of Extraembryonic Membranes Extends beyond Placental Amniotes
por: Albergotti, Lori C., et al.
Publicado: (2009)

Proteasome inhibitors prevent bi-directional HER2/estrogen-receptor cross-talk leading to cell death in endocrine and lapatinib-resistant HER2+/ER+ breast cancer cells
por: Thaler, Sonja, et al.
Publicado: (2017)

Unraveling the Molecular Nexus between GPCRs, ERS, and EMT
por: Kumari, Niti, et al.
Publicado: (2021)

Pituitary, Gonadal, Thyroid Hormones and Endocrine Disruptors in Pre and Postmenopausal Nigerian Women with ER-, PR- and HER-2-Positive and Negative Breast Cancers
por: Ajayi, Olulope, et al.
Publicado: (2018)

Automated Quantification of Extranuclear ERα Using Phosphor-Integrated Dots for Predicting Endocrine Therapy Resistance in HR(+)/HER2(−) Breast Cancer
por: Guo, Zhaorong, et al.
Publicado: (2019)

Utility of Ki67 labeling index, cyclin D1 expression, and ER-activity level in postmenopausal ER-positive and HER2-negative breast cancer with neoadjuvant chemo-endocrine therapy
por: Kurozumi, Sasagu, et al.
Publicado: (2019)

Breakthrough Therapy Designation Criteria Identify Drugs that Improve Clinical Outcomes for Patients: A Case for More Streamlined Coverage of Promising Therapies
por: Collins, Grace, et al.
Publicado: (2023)

Unraveling flp-11/flp-32 dichotomy in nematodes
por: Atkinson, Louise E., et al.
Publicado: (2016)

Unraveling the Link Between Periodontal Disease and High Cholesterol: A Cross-Sectional Study
por: Khan, Tooba Zahid, et al.
Publicado: (2023)

Structural Mechanism of ER Retrieval of MHC Class I by Cowpox
por: McCoy, William H., et al.
Publicado: (2012)

Health-related quality of life and estimation of the minimally important difference in the Functional Assessment of Cancer Therapy-Endocrine Symptom score in postmenopausal ER+/HER2- metastatic breast cancer with low sensitivity to endocrine therapy
por: Kikawa, Yuichiro, et al.
Publicado: (2022)

Unraveling the complexity of human behavior and urbanization on community vulnerability to floods
por: Hemmati, Mona, et al.
Publicado: (2021)

Automated Tumour Recognition and Digital Pathology Scoring Unravels New Role for PD-L1 in Predicting Good Outcome in ER-/HER2+ Breast Cancer
por: Humphries, Matthew P., et al.
Publicado: (2018)

ECM1 is associated with endocrine resistance in ER(+) breast cancers
por: Lee, Tae Won, et al.
Publicado: (2022)

Resistance Mechanisms to Combined CDK4/6 Inhibitors and Endocrine Therapy in ER+/HER2− Advanced Breast Cancer: Biomarkers and Potential Novel Treatment Strategies
por: Al-Qasem, Abeer J., et al.
Publicado: (2021)

Impact of combining the progesterone receptor and preoperative endocrine prognostic index (PEPI) as a prognostic factor after neoadjuvant endocrine therapy using aromatase inhibitors in postmenopausal ER positive and HER2 negative breast cancer
por: Kurozumi, Sasagu, et al.
Publicado: (2018)

ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer
por: Pinhel, Isabel, et al.
Publicado: (2012)

Aging versus youth: Endocrine aspects of vulnerability for COVID-19
por: Oguz, Seda Hanife, et al.
Publicado: (2021)

Targeted isolation and cultivation of uncultivated bacteria by reverse genomics
por: Cross, Karissa L., et al.
Publicado: (2019)

Editorial: Unraveling vulnerability factors in addiction drug use and potential treatments
por: Montesinos, Jorge, et al.
Publicado: (2022)

Comparative Analysis of Microbial Diversity Across Temperature Gradients in Hot Springs From Yellowstone and Iceland
por: Podar, Peter T., et al.
Publicado: (2020)

Complete Genome Sequence of Human Oral Actinomyces sp. HMT175 Strain ORNL0102, a Host of the Saccharibacterium (TM7) HMT957
por: Joshi, Snehal, et al.
Publicado: (2021)

Targeted therapies for ER+/HER2- metastatic breast cancer
por: Yamamoto-Ibusuki, Mutsuko, et al.
Publicado: (2015)

An estrogen receptor (ER)‐related signature in predicting prognosis of ER‐positive breast cancer following endocrine treatment
por: Tang, Jianing, et al.
Publicado: (2019)

The interaction between ER and NFκB in resistance to endocrine therapy
por: Sas, Leen, et al.
Publicado: (2012)

Male balding as a major risk factor for severe COVID-19: A possible role for targeting androgens and transmembrane protease serine 2 to protect vulnerable individuals
por: Wambier, Carlos Gustavo, et al.
Publicado: (2020)

Prognostic Significance of High Expression of ER-beta in Surgically Treated ER-Positive Breast Cancer Following Endocrine Therapy
por: Kim, Tae-Jung, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_lb0pv15aga8ohesr1mnac8dec2